Scalable synthesis of a nucleoside phosphoramidate prodrug inhibitor of HCV NS5B RDRP: Challenges in the production of a diastereomeric mixture
A scalable process is described for the synthesis of 2′-C-methylguanosine-5′-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl-N-benzylphosphoramidate], a nucleotide prodrug inhibitor of hepatitis C virus NS5B polymerase. The route features the use of ph
Mayes, Benjamin A.,Wang, Jingyang,Arumugasamy, Jeevanandam,Arunachalam, Kannan,Baloglu, Erkan,Bauer, David,Becker, Alan,Chaudhuri, Narayan,Glynn, Roberta,Latham, G. Mark,Li, Jie,Lim, Jinsoo,Liu, Jia,Mathieu, Steve,McGarry, F. Patrick,Rosinovsky, Elodie,Soret, Adrien F.,Stewart, Alistair,Moussa, Adel
p. 520 - 530
(2015/04/27)
COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
-
Page/Page column 176
(2008/12/07)
More Articles about upstream products of 1036915-08-8